intetumumab

Intetumumab is a fully human monoclonal antibody that targets the αv integrin family, specifically binding to and blocking both integrin alphaVbeta3 (αvβ3) and integrin alphaVbeta5 (αvβ5). By inhibiting these integrins, intetumumab disrupts integrin-mediated tumor angiogenesis and tumor growth. This antiangiogenic effect results in the inhibition of cell adhesion, migration, proliferation, and invasion of both tumor and endothelial cells. Intetumumab was developed primarily for oncology indications such as malignant melanoma and prostate cancer but development has been discontinued. The drug was originally developed by Centocor (now Janssen Biotech), with later involvement from Janssen-Cilag[1][2][3][4].

Other names

intetumumab